Evaluation of the Results of Simultaneous Pancreatic and Hepatic Resections for Metastatic Neuroendocrine Tumors.

Completed

• Conditions: Tumor of Pancreas

• Registration Number: NCT05528614
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

The indications for synchronous liver resection for metastatic neuroendocrine tumors of pancreatic origin remain debated and poorly described in the literature.

The reported mortality of this type of simultaneous resection remains very high, especially when a cephalic duodenopancreatectomy is associated with a hepatic resection (up to 40%). The benefit in terms of survival remains to be evaluated. The ReSiPaTNE study proposes to create a retrospective cohort of simultaneous pancreatic and hepatic resections for metastatic neuroendocrine tumors in order to evaluate the short and long term results of this type of resection. The evaluation of the results of this type of resection may be useful for the selection of patients for treatment.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-01-13
• Status Verified: 2022-08
• Study First Submitted: 2022-08-29
• Study First Submitted QC: 2022-09-01
• Study First Posted: 2022-09-06
• Primary Completion: 2022-11-13
• Study Completion: 2023-01-13
• Last Update Submitted: 2023-11-07
• Last Update Posted: 2023-11-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 51

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Postoperative morbidity and mortality of simultaneous pancreatic and hepatic resectio	Morbidity and mortality at 90 postoperative days

Trial Locations

Locations (1)

Service de Chirurgie Générale, Hépatique, Endocrinienne et Transplantation - CHU de Strasbourg - France; 🇫🇷 Strasbourg, France